Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cetuximab added to chemoradiotherapy for locally advanced anal canal cancer
2007-007029-38Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, cisplatin and fluorouracil in anal squamous cell carcinoma (SCCA), sponsored by Unicancer. Primary endpoint: Objective tumor response. Started Jul 2008; status: completed.
02
Drugs
cetuximabcisplatinfluorouracil
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2007-007029-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007029-38.